1-20 of 23
Elisabeth G.E. de Vries
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Integrating Molecular Imaging and Transcriptomic Profiling in Advanced HER2-Positive Breast Cancer Receiving Trastuzumab Emtansine: An Analysis of the ZEPHIR Clinical Trial

Mattia Rediti, Danai Fimereli, Magdalena Mileva, Zéna Wimana, David Venet, Patrick Flamen, Thomas Guiot, Elisabeth G.E. de Vries, Carolien P. Schröder, Catharina Willemien Menke-van der Houven van Oordt, Marion Maetens, Samira Majjaj, Denis Larsimont, Françoise Rothé, Christos Sotiriou, Géraldine Gebhart
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (1): 110–121.
https://doi.org/10.1158/1078-0432.CCR-24-1007
Published: 06 January 2025
View article titled, Integrating Molecular Imaging and Transcriptomic Profiling in Advanced HER2-Positive Breast Cancer Receiving Trastuzumab Emtansine: An Analysis of the ZEPHIR Clinical Trial
Open the PDF for Integrating Molecular Imaging and Transcriptomic Profiling in Advanced HER2-Positive Breast Cancer Receiving Trastuzumab Emtansine: An Analysis of the ZEPHIR Clinical Trial in another window
Includes: Supplementary data
Journal Articles

Facts and Hopes for PET Imaging–Derived Immunotherapy Biomarkers

Derk Jan A. de Groot, Marjolijn N. Lub-de Hooge, Tom van Meerten, Adrienne H. Brouwers, Elisabeth G.E. de Vries
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (23): 5252–5259.
https://doi.org/10.1158/1078-0432.CCR-24-1427
Published: 02 December 2024
View article titled, Facts and Hopes for PET Imaging–Derived Immunotherapy Biomarkers
Open the PDF for Facts and Hopes for PET Imaging–Derived Immunotherapy Biomarkers in another window
Journal Articles

Plasma ctDNA as a Treatment Response Biomarker in Metastatic Cancers: Evaluation by the RECIST Working Group

Alexander W. Wyatt, Saskia Litiere, Francois-Clément Bidard, Luc Cabel, Lars Dyrskjøt, Chris A. Karlovich, Klaus Pantel, Joan Petrie, Reena Philip, Hillary S. Andrews, Paz J. Vellanki, Sofie H. Tolmeijer, Xenia Villalobos Alberu, Christian Alfano, Jan Bogaerts, Emiliano Calvo, Alice P. Chen, Rodrigo A. Toledo, Elisabeth G.E. de Vries, Lesley Seymour, Scott A. Laurie, Elena Garralda, for the RECIST ctDNA workshop group
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (22): 5034–5041.
https://doi.org/10.1158/1078-0432.CCR-24-1883
Published: 15 November 2024
View article titled, Plasma ctDNA as a Treatment Response Biomarker in Metastatic Cancers: Evaluation by the RECIST Working Group
Open the PDF for Plasma ctDNA as a Treatment Response Biomarker in Metastatic Cancers: Evaluation by the RECIST Working Group in another window
Journal Articles

[18F]FDG and [18F]FES PET/CT Imaging as a Biomarker for Therapy Effect in Patients with Metastatic ER+ Breast Cancer Undergoing Treatment with Rintodestrant

Ramsha Iqbal, Maqsood Yaqub, Huseyyin O. Bektas, Daniela E. Oprea-Lager, Elisabeth G.E. de Vries, Andor W.J.M. Glaudemans, Philippe Aftimos, Géraldine Gebhart, Andrew P. Beelen, Robert C. Schuit, Albert D. Windhorst, Ronald Boellaard, C. Willemien Menke-van der Houven van Oordt
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (11): 2075–2084.
https://doi.org/10.1158/1078-0432.CCR-22-2720
Published: 01 June 2023
View article titled, [<sup>18</sup>F]FDG and [<sup>18</sup>F]FES PET/CT Imaging as a Biomarker for Therapy Effect in Patients with Metastatic ER+ Breast Cancer Undergoing Treatment with Rintodestrant
Open the PDF for [<sup>18</sup>F]FDG and [<sup>18</sup>F]FES PET/CT Imaging as a Biomarker for Therapy Effect in Patients with Metastatic ER+ Breast Cancer Undergoing Treatment with Rintodestrant in another window
Includes: Supplementary data
Journal Articles

First-in-Human Study of the Biodistribution and Pharmacokinetics of 89Zr-CX-072, a Novel Immunopet Tracer Based on an Anti–PD-L1 Probody

Laura Kist de Ruijter, Jahlisa S. Hooiveld-Noeken, Danique Giesen, Marjolijn N. Lub-de Hooge, Iris C. Kok, Adrienne H. Brouwers, Sjoerd G. Elias, Margaret T.L. Nguyen, Hong Lu, Jourik A. Gietema, Mathilde Jalving, Derk J.A. de Groot, Olga Vasiljeva, Elisabeth G.E. de Vries
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (19): 5325–5333.
https://doi.org/10.1158/1078-0432.CCR-21-0453
Published: 01 October 2021
View article titled, First-in-Human Study of the Biodistribution and Pharmacokinetics of <sup>89</sup>Zr-CX-072, a Novel Immunopet Tracer Based on an Anti–PD-L1 Probody
Open the PDF for First-in-Human Study of the Biodistribution and Pharmacokinetics of <sup>89</sup>Zr-CX-072, a Novel Immunopet Tracer Based on an Anti–PD-L1 Probody in another window
Includes: Supplementary data
Journal Articles

Probody Therapeutic Design of 89Zr-CX-072 Promotes Accumulation in PD-L1–Expressing Tumors Compared to Normal Murine Lymphoid Tissue

Danique Giesen, Linda N. Broer, Marjolijn N. Lub-de Hooge, Irina Popova, Bruce Howng, Margaret Nguyen, Olga Vasiljeva, Elisabeth G.E. de Vries, Martin Pool
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (15): 3999–4009.
https://doi.org/10.1158/1078-0432.CCR-19-3137
Published: 03 August 2020
View article titled, Probody Therapeutic Design of <sup>89</sup>Zr-CX-072 Promotes Accumulation in PD-L1–Expressing Tumors Compared to Normal Murine Lymphoid Tissue
Open the PDF for Probody Therapeutic Design of <sup>89</sup>Zr-CX-072 Promotes Accumulation in PD-L1–Expressing Tumors Compared to Normal Murine Lymphoid Tissue in another window
Includes: Supplementary data
Journal Articles

Design and Conduct of Early Clinical Studies of Immunotherapy: Recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies 2019 (MDICT)

Martin Smoragiewicz, Alex A. Adjei, Emiliano Calvo, Josep Tabernero, Aurélien Marabelle, Christophe Massard, Jun Tang, Elisabeth G.E. de Vries, Jean-Yves Douillard, Lesley Seymour
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (11): 2461–2465.
https://doi.org/10.1158/1078-0432.CCR-19-3136
Published: 01 June 2020
View article titled, Design and Conduct of Early Clinical Studies of Immunotherapy: Recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies 2019 (MDICT)
Open the PDF for Design and Conduct of Early Clinical Studies of Immunotherapy: Recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies 2019 (MDICT) in another window
Journal Articles

89Zr-labeled Bispecific T-cell Engager AMG 211 PET Shows AMG 211 Accumulation in CD3-rich Tissues and Clear, Heterogeneous Tumor Uptake

Kirsten L. Moek, Stijn J.H. Waaijer, Iris C. Kok, Frans V. Suurs, Adrienne H. Brouwers, C. Willemien Menke-van der Houven van Oordt, Thijs T. Wind, Jourik A. Gietema, Carolien P. Schröder, Shekar V.K. Mahesh, Annelies Jorritsma-Smit, Marjolijn N. Lub-de Hooge, Rudolf S.N. Fehrmann, Derk Jan A. de Groot, Elisabeth G.E. de Vries
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (12): 3517–3527.
https://doi.org/10.1158/1078-0432.CCR-18-2918
Published: 14 June 2019
View article titled, <sup>89</sup>Zr-labeled Bispecific T-cell Engager AMG 211 PET Shows AMG 211 Accumulation in CD3-rich Tissues and Clear, Heterogeneous Tumor Uptake
Open the PDF for <sup>89</sup>Zr-labeled Bispecific T-cell Engager AMG 211 PET Shows AMG 211 Accumulation in CD3-rich Tissues and Clear, Heterogeneous Tumor Uptake in another window
Includes: Supplementary data
Journal Articles

Molecular Imaging of Radiolabeled Bispecific T-Cell Engager 89Zr-AMG211 Targeting CEA-Positive Tumors

Stijn J.H. Waaijer, Frank J. Warnders, Sabine Stienen, Matthias Friedrich, Alexander Sternjak, H. Kam Cheung, Anton G.T. Terwisscha van Scheltinga, Carolien P. Schröder, Elisabeth G.E. de Vries, Marjolijn N. Lub-de Hooge
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (20): 4988–4996.
https://doi.org/10.1158/1078-0432.CCR-18-0786
Published: 15 October 2018
View article titled, Molecular Imaging of Radiolabeled Bispecific T-Cell Engager <sup>89</sup>Zr-AMG211 Targeting CEA-Positive Tumors
Open the PDF for Molecular Imaging of Radiolabeled Bispecific T-Cell Engager <sup>89</sup>Zr-AMG211 Targeting CEA-Positive Tumors in another window
Includes: Supplementary data
Journal Articles

89Zr-Lumretuzumab PET Imaging before and during HER3 Antibody Lumretuzumab Treatment in Patients with Solid Tumors

Frederike Bensch, Laetitia E. Lamberts, Michaël M. Smeenk, Annelies Jorritsma-Smit, Marjolijn N. Lub-de Hooge, Anton G.T. Terwisscha van Scheltinga, Johan R. de Jong, Jourik A. Gietema, Carolien P. Schröder, Marlene Thomas, Wolfgang Jacob, Keelara Abiraj, Celine Adessi, Georgina Meneses-Lorente, Ian James, Martin Weisser, Adrienne H. Brouwers, Elisabeth G.E. de Vries
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (20): 6128–6137.
https://doi.org/10.1158/1078-0432.CCR-17-0311
Published: 12 October 2017
View article titled, <sup>89</sup>Zr-Lumretuzumab PET Imaging before and during HER3 Antibody Lumretuzumab Treatment in Patients with Solid Tumors
Open the PDF for <sup>89</sup>Zr-Lumretuzumab PET Imaging before and during HER3 Antibody Lumretuzumab Treatment in Patients with Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Tumor-Specific Uptake of Fluorescent Bevacizumab–IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study

Laetitia E. Lamberts, Maximillian Koch, Johannes S. de Jong, Arthur L.L. Adams, Jürgen Glatz, Mariëtte E.G. Kranendonk, Anton G.T. Terwisscha van Scheltinga, Liesbeth Jansen, Jakob de Vries, Marjolijn N. Lub-de Hooge, Carolien P. Schröder, Annelies Jorritsma-Smit, Matthijs D. Linssen, Esther de Boer, Bert van der Vegt, Wouter B. Nagengast, Sjoerd G. Elias, Sabrina Oliveira, Arjen J. Witkamp, Willem P.Th.M. Mali, Elsken Van der Wall, Paul J. van Diest, Elisabeth G.E. de Vries, Vasilis Ntziachristos, Gooitzen M. van Dam
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (11): 2730–2741.
https://doi.org/10.1158/1078-0432.CCR-16-0437
Published: 31 May 2017
View article titled, Tumor-Specific Uptake of Fluorescent Bevacizumab–IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study
Open the PDF for Tumor-Specific Uptake of Fluorescent Bevacizumab–IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study in another window
Includes: Multimedia, Supplementary data
Journal Articles

Abstract A37: Dual wavelength near-infrared fluorescence imaging of VEGF-A and IGF-1R in ovarian cancer patient-derived xenografts

Tushar Tomar, Nicolette G. Alkema, Jolanda A.L. Visser, Anton G. Terwisscha van Scheltinga, Gert Jan Meersma, Harry G. Klip, Evelien W. Duiker, Elisabeth G.E. De Vries, Ate G.J. Van der Zee, Steven De Jong
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (16_Supplement): A37.
https://doi.org/10.1158/1557-3265.PDX16-A37
Published: 15 August 2016
View article titled, Abstract A37: Dual wavelength near-infrared fluorescence imaging of VEGF-A and IGF-1R in ovarian cancer patient-derived xenografts
Journal Articles

ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody–Drug Conjugate Treatment

Laetitia E. Lamberts, Catharina W. Menke-van der Houven van Oordt, Eva J. ter Weele, Frederike Bensch, Michiel M. Smeenk, Johannes Voortman, Otto S. Hoekstra, Simon P. Williams, Bernard M. Fine, Daniel Maslyar, Johan R. de Jong, Jourik A. Gietema, Carolien P. Schröder, Alphons H.H. Bongaerts, Marjolijn N. Lub-de Hooge, Henk M.W. Verheul, Sandra M. Sanabria Bohorquez, Andor W.J.M. Glaudemans, Elisabeth G.E. de Vries
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (7): 1642–1652.
https://doi.org/10.1158/1078-0432.CCR-15-1272
Published: 31 March 2016
View article titled, ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody–Drug Conjugate Treatment
Open the PDF for ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody–Drug Conjugate Treatment in another window
Includes: Supplementary data
Journal Articles

89Zr-trastuzumab and 89Zr-bevacizumab PET to Evaluate the Effect of the HSP90 Inhibitor NVP-AUY922 in Metastatic Breast Cancer Patients

Sietske B.M. Gaykema, Carolien P. Schröder, Joanna Vitfell-Rasmussen, Sue Chua, Thijs H. Oude Munnink, Adrienne H. Brouwers, Alfons H.H. Bongaerts, Mikhail Akimov, Cristina Fernandez-Ibarra, Marjolijn N. Lub-de Hooge, Elisabeth G.E. de Vries, Charles Swanton, Udai Banerji
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2014) 20 (15): 3945–3954.
https://doi.org/10.1158/1078-0432.CCR-14-0491
Published: 31 July 2014
View article titled, <sup>89</sup>Zr-trastuzumab and <sup>89</sup>Zr-bevacizumab PET to Evaluate the Effect of the HSP90 Inhibitor NVP-AUY922 in Metastatic Breast Cancer Patients
Open the PDF for <sup>89</sup>Zr-trastuzumab and <sup>89</sup>Zr-bevacizumab PET to Evaluate the Effect of the HSP90 Inhibitor NVP-AUY922 in Metastatic Breast Cancer Patients in another window
Includes: Supplementary data
Journal Articles

Measurement of Tumor VEGF-A Levels with 89Zr-Bevacizumab PET as an Early Biomarker for the Antiangiogenic Effect of Everolimus Treatment in an Ovarian Cancer Xenograft Model

Arne R.M. van der Bilt, Anton G.T. Terwisscha van Scheltinga, Hetty Timmer-Bosscha, Carolien P. Schröder, Linda Pot, Jos G.W. Kosterink, Ate G.J. van der Zee, Marjolijn N. Lub-de Hooge, Steven de Jong, Elisabeth G.E. de Vries, Anna K.L. Reyners
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (22): 6306–6314.
https://doi.org/10.1158/1078-0432.CCR-12-0406
Published: 14 November 2012
View article titled, Measurement of Tumor VEGF-A Levels with <sup>89</sup>Zr-Bevacizumab PET as an Early Biomarker for the Antiangiogenic Effect of Everolimus Treatment in an Ovarian Cancer Xenograft Model
Open the PDF for Measurement of Tumor VEGF-A Levels with <sup>89</sup>Zr-Bevacizumab PET as an Early Biomarker for the Antiangiogenic Effect of Everolimus Treatment in an Ovarian Cancer Xenograft Model in another window
Includes: Supplementary data
Journal Articles

Involvement of the TGF-β and β-Catenin Pathways in Pelvic Lymph Node Metastasis in Early-Stage Cervical Cancer

Maartje G. Noordhuis, Rudolf S.N. Fehrmann, G. Bea A. Wisman, Esther R. Nijhuis, Jelmer J. van Zanden, Perry D. Moerland, Emiel Ver Loren van Themaat, Haukeline H. Volders, Mirjam Kok, Klaske A. ten Hoor, Harry Hollema, Elisabeth G.E. de Vries, Geertruida H. de Bock, Ate G.J. van der Zee, Ed Schuuring
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (6): 1317–1330.
https://doi.org/10.1158/1078-0432.CCR-10-2320
Published: 15 March 2011
View article titled, Involvement of the TGF-β and β-Catenin Pathways in Pelvic Lymph Node Metastasis in Early-Stage Cervical Cancer
Open the PDF for Involvement of the TGF-β and β-Catenin Pathways in Pelvic Lymph Node Metastasis in Early-Stage Cervical Cancer in another window
Includes: Supplementary data
Journal Articles

Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study

Constantijne H. Mom, Jaap Verweij, Corina N.A.M. Oldenhuis, Jourik A. Gietema, Norma Lynn Fox, Renée Miceli, Ferry A.L.M. Eskens, Walter J. Loos, Elisabeth G.E. de Vries, Stefan Sleijfer
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (17): 5584–5590.
https://doi.org/10.1158/1078-0432.CCR-09-0996
Published: 31 August 2009
View article titled, Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study
Open the PDF for Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study in another window
Includes: Supplementary data
Journal Articles

Combining Simvastatin with the Farnesyltransferase Inhibitor Tipifarnib Results in an Enhanced Cytotoxic Effect in a Subset of Primary CD34+ Acute Myeloid Leukemia Samples

Karen van der Weide, Susan D.P.W.M. de Jonge-Peeters, Folkert Kuipers, Elisabeth G.E. de Vries, Edo Vellenga
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (9): 3076–3083.
https://doi.org/10.1158/1078-0432.CCR-08-3004
Published: 30 April 2009
View article titled, Combining Simvastatin with the Farnesyltransferase Inhibitor Tipifarnib Results in an Enhanced Cytotoxic Effect in a Subset of Primary CD34<sup>+</sup> Acute Myeloid Leukemia Samples
Open the PDF for Combining Simvastatin with the Farnesyltransferase Inhibitor Tipifarnib Results in an Enhanced Cytotoxic Effect in a Subset of Primary CD34<sup>+</sup> Acute Myeloid Leukemia Samples in another window
Journal Articles

Enhanced Antitumor Efficacy of a DR5-Specific TRAIL Variant over Recombinant Human TRAIL in a Bioluminescent Ovarian Cancer Xenograft Model

Evelien W. Duiker, Elisabeth G.E. de Vries, Devalingam Mahalingam, Gert Jan Meersma, Wytske Boersma-van Ek, Harry Hollema, Marjolijn N. Lub-de Hooge, Go M. van Dam, Robbert H. Cool, Wim J. Quax, Afshin Samali, Ate G.J. van der Zee, Steven de Jong
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (6): 2048–2057.
https://doi.org/10.1158/1078-0432.CCR-08-1535
Published: 16 March 2009
View article titled, Enhanced Antitumor Efficacy of a DR5-Specific TRAIL Variant over Recombinant Human TRAIL in a Bioluminescent Ovarian Cancer Xenograft Model
Open the PDF for Enhanced Antitumor Efficacy of a DR5-Specific TRAIL Variant over Recombinant Human TRAIL in a Bioluminescent Ovarian Cancer Xenograft Model in another window
Includes: Supplementary data
Journal Articles

TRAIL Induces Apoptosis in Human Colorectal Adenoma Cell Lines and Human Colorectal Adenomas

Mathilde Jalving, Steven de Jong, Jan J. Koornstra, Wytske Boersma-van Ek, Nynke Zwart, Jelle Wesseling, Elisabeth G.E. de Vries, Jan H. Kleibeuker
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (14): 4350–4356.
https://doi.org/10.1158/1078-0432.CCR-05-2487
Published: 20 July 2006
View article titled, TRAIL Induces Apoptosis in Human Colorectal Adenoma Cell Lines and Human Colorectal Adenomas
Open the PDF for TRAIL Induces Apoptosis in Human Colorectal Adenoma Cell Lines and Human Colorectal Adenomas in another window